|
Market Cap (5-Jun) $102,067,456 (1,050th) |
Close (30-Jun) $0.062 |
Volume (30-Jun) 526,676 |
Shortsold (26-May) 683,172 (0.11%) (444th) |
|
52w High $0.67 |
52w Low $0.165 |
P/E 10.78 |
EPS -0.03 |
DXB released this announcement to the ASX on 7 February 2022, 10:46. The announcement is not marked as price sensitive, and is 2 page(s) in length and 298.7kb in size.
You can view all announcements from DXB and see how they appear on a price chart on the announcements page.
At the date of this announcement, DXB was 0.002% short sold according to ASIC data. It was ranked the 680th most shorted stock on the ASX. It is now ranked as the 444th most shorted stock on the ASX with 0.114% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from DXB | |
|---|---|
| Application for quotation of securities - DXB | 29 June 2023, 9:01 |
| Application for quotation of securities - DXB | 29 June 2023, 9:00 |
| Application for quotation of securities - DXB | 29 June 2023, 8:59 |
| Dimerix Appoints Chief Medical Officer | 7 February 2022, 10:46 |
| First Regulatory Approval in Europe for DMX-200 FSGS Study | 1 February 2022, 11:50 |
| Quarterly Appendix 4C and Activities Report | 28 January 2022, 8:55 |
| Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India | 11 January 2022, 9:50 |
You must be logged in to post a reply.
Dimerix 